A PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTORMODIFIED T CELLS DIRECTED AGAINST CD19 IN PATIENTS WITH RELAPSED OR REFRACTORYCD19(+) B CELL LYMPHOMAS: INTERIM ANALYSIS

Zhitao Ying,X. Xiang,Yuqin Song,N. Ding,Y. Lin,Wen Zheng,Xiaopei Wang,Ningjing Lin,Meifeng Tu,Yan Xie,Chen Zhang,Weiping Liu,Lijuan Deng,Y. Liu,Y. Yue,X. Yu,H. Liu,P. Duan,F. Chen,X. Wu,X.F. Huang,L. Jones,X. Kang,S. Chen,Jun Zhu

DOI: https://doi.org/10.1002/hon.2438_131

IF: 4.85

2017-01-01

Hematological Oncology

Abstract:Introduction: Patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) have poor outcomes with currently available strategies. Based on the promising results seen in patients treated with anti-CD19 CAR T-cell therapy in R/R B-NHL, we initiated the phase I study evaluating the safety and efficacy in patients with R/R B-NHL (NCT02842138). Autologous T cells were genetically modified to express a chimeric antigen receptor consisting of an anti-CD19-scFv domain with CD3ζ and 4-1BB signaling domains. Methods: Patients received CAR T-cell infusion after a conditioning regimen of cyclophosphamide (250 mg/m2) and fludarabine (25 mg/m2) daily for 3 days. Three CAR T cell doses were tested: 5 × 104, 1 × 105, and 1 × 106 CAR T cells/kg, respectively. Primary endpoints include safety and pharmacokinetics (PK) of CAR T cells. Secondary endpoints include complete and overall response (CR, OR) rates and duration of response (DOR) per International Working Group Criteria (Cheson, J ClinOncol2007). Results: As of March 2017, 14 patients were enrolled, 10 patients underwent response evaluation. Median age of the 10 evaluable patients was 37 years (range 24–68), 4 females and 6 males, 3 follicular lymphoma (FL) and 7 diffuse large B-cell lymphoma (DLBCL). Median number of prior therapies was 2.5 (range 2–7). The first group of three patients (2 FL and 1 DLBCL) received 5 × 104 CAR T cells/kg. Two FL patients achieved partial remission (PR) on day 28, and one of the patients achieved complete remission (CR) 3 months later. The second group of three patients (1 FL and 2 DLBCL) received 1 × 105 CAR T cells/kg. The FL patient achieved PR on day 28. The last group of four patients (all were diagnosed with DLBCL) received 1 × 106 CAR T cells/kg. Three patients achieved PR on day 28 (75%). One patient attained PD on day 28 and died 10 days later due to disease progression. A significant CAR T-cell expansion was detected in this case. On day 26, 26.8% of her PBMC were CAR T cells. Interestingly, PD1 expression was significant in her expanded CAR T cells. Approximately 78.3% of CD8+ CAR T cells and 71.4% of CD4+ CAR T cells expressed PD1 on day 26, as compared to 22% and 42% on day 13, respectively. Increased PD1-expressing CAR T cells were also found in other patients' peripheral blood. No serious adverse event (sAE) was observed in all patients. Two patients experienced mild fever (grade 1–2). In vivo expansion of CAR T cells was detected in all patients between day14 and 28. All responding patients are still in remission at the last follow-up (Range: 2.5–9 months). Conclusions: This study demonstrated early promising activity of anti-CD19 CAR T cells in patients with R/R B-NHL. The toxicities of CRS were mild and manageable. Our study also provided the first clinical evidence that expanded CAR T cells could express PD1. Blocking PD1 pathway may enhance the effector function of CAR T cells and improve the clinical outcomes of CAR T-cell therapy. Keywords: B-cell lymphoma; CD19; immune system.